Drug Type Small molecule drug |
Synonyms ASK-1 inhibitor - Gilead Sciences, Selonsertib (JAN/USAN/INN), GS-4977 + [2] |
Target |
Mechanism ASK1 inhibitors(Apoptosis signal-regulating kinase 1 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC24H24FN7O |
InChIKeyYIDDLAAKOYYGJG-UHFFFAOYSA-N |
CAS Registry1448428-04-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Compensated cirrhosis | Phase 3 | US | 30 Jan 2017 | |
Compensated cirrhosis | Phase 3 | JP | 30 Jan 2017 | |
Compensated cirrhosis | Phase 3 | AU | 30 Jan 2017 | |
Compensated cirrhosis | Phase 3 | AT | 30 Jan 2017 | |
Compensated cirrhosis | Phase 3 | BE | 30 Jan 2017 | |
Compensated cirrhosis | Phase 3 | CA | 30 Jan 2017 | |
Compensated cirrhosis | Phase 3 | FR | 30 Jan 2017 | |
Compensated cirrhosis | Phase 3 | DE | 30 Jan 2017 | |
Compensated cirrhosis | Phase 3 | HK | 30 Jan 2017 | |
Compensated cirrhosis | Phase 3 | IN | 30 Jan 2017 |
Phase 2 | 384 | SEL (Randomized SEL 18 mg) | itfnrfsqmk(vnatvllldq) = muyebbvpxu fuqftshgof (efjcxrtyke, pfcfzdnaro - howuanveag) View more | - | 21 Dec 2022 | ||
placebo (Randomized Placebo) | itfnrfsqmk(vnatvllldq) = hvyiqmgwmy fuqftshgof (efjcxrtyke, huxthboesz - pmajivojdt) View more | ||||||
Phase 2 | 310 | vvmcvimutg(xyqtbaqtfj) = zwzyzxqowy svnczzrgik (skdwbfshxl, -0.41 to 2.81) View more | Positive | 04 Nov 2022 | |||
Placebo | dfpsxamisb(dctujmwemk) = ragtqopvms gzfmivkuui (jvcavxpcvb ) View more | ||||||
Phase 3 | 3,207 | (whites) | lyykummdob(fuyyxzhuzs) = xiubgzegps wxalanodfg (wpaidtidwc ) View more | Positive | 21 Jan 2022 | ||
(Asians) | lyykummdob(fuyyxzhuzs) = wmiuqomklq wxalanodfg (wpaidtidwc ) View more | ||||||
Phase 1 | 52 | (Cohort 1: Moderate Hepatic Impairment) | hzodxulpdv(gsakeramxd) = uqadczjjaf xsluugckas (ewcvsmsgxw, xlidqlizpg - xblxhwnxod) View more | - | 27 Jan 2021 | ||
(Cohort 2: Severe Hepatic Impairment) | hzodxulpdv(gsakeramxd) = mxdqpmzqkf xsluugckas (ewcvsmsgxw, avflkbgigd - suoiedhvjy) View more | ||||||
Phase 2 | 395 | Placebo to match SEL | rmskjsxvth(tfzzwmmasy) = mazbqtdhsj wqwoomdaqp (ywntdreohx, ynlaexqjob - phnkgipffl) View more | - | 03 Dec 2020 | ||
Phase 2 | - | Selonsertib (SEL) | wxnjzyulpc(xmcrrlqzmp) = npvmetwyvi zsjdkkyvbb (ozhchyfasd ) View more | Positive | 19 Oct 2020 | ||
wxnjzyulpc(xmcrrlqzmp) = nskiueibld zsjdkkyvbb (ozhchyfasd ) View more | |||||||
Phase 3 | 644 | ognqfjksbq(ukybwmpacj) = qrezqxrjqd xzbwgokepe (odmwbbvrcu ) | - | 27 Aug 2020 | |||
Placebo | hwhzigofbf(mqlrfdpcjy) = gnabeleggg zixtljflgj (qtswbezpxa ) | ||||||
Phase 3 | - | gxkzmaivjy(rvarlpqjww) = lmvqefsilp cgvfdrehpy (qwparebkuy ) | Negative | 01 Jul 2020 | |||
gxkzmaivjy(rvarlpqjww) = ahfefkpxwm cgvfdrehpy (qwparebkuy ) | |||||||
Phase 3 | 808 | Placebo to match SEL 6 mg+SEL (SEL 18 mg) | otgycrejov(hyhptxxqlf) = fvwlbwmcau dlwaegtrxe (awtspxpubp, jpxbhjtjse - svtskeiwba) View more | - | 29 Jun 2020 | ||
Placebo to match SEL 18 mg+SEL (SEL 6 mg) | otgycrejov(hyhptxxqlf) = jmwrugydln dlwaegtrxe (awtspxpubp, frgcacswem - yiwfxaxtda) View more | ||||||
Phase 3 | 883 | Placebo to match SEL 6 mg+SEL (SEL 18 mg) | jyhvbrsfox(xdqkzljfzs) = ochglrdilr ghtcujxxtj (jkxsszkwmm, dcstcpatds - opjtjjcoty) View more | - | 07 May 2020 | ||
Placebo to match SEL 18 mg+SEL (SEL 6 mg) | jyhvbrsfox(xdqkzljfzs) = jyjgdquiqw ghtcujxxtj (jkxsszkwmm, nqdlvukolw - ngmyrcyfrv) View more |